Cutaneous T-cell Lymphoma Market Outlook 2034: Growth Trends, Competitive Landscape, and Future Opportunities - DelveInsight

DelveInsight's "Cutaneous T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Cutaneous T-cell Lymphoma, historical and forecasted epidemiology as well as the Cutaneous T-cell Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cutaneous T-cell Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cutaneous T-cell Lymphoma Market Forecast
https://www.delveinsight.com/sample-request/cutaneous-t-cell-lymphoma-ctcl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Cutaneous T-cell Lymphoma Market Report:
• The Cutaneous T-Cell Lymphoma market size across the 7MM was estimated at around USD 1,042 million in 2025 and is expected to grow at a CAGR of 5.0%, reaching approximately USD 1,622 million by 2034 in the major markets of the US, EU4, the UK, and Japan.
• In August 2026, Swedish Orphan Biovitrum (Sobi) has entered into an agreement with Innate Pharma to license lacutamab, an investigational therapy for cutaneous T-cell lymphoma (CTCL), in a deal valued at up to $580 million. The agreement includes a $75 million upfront payment to support the pivotal Phase III TELLOMAK-3 trial, which is intended to underpin an accelerated approval application in Sézary syndrome and potential full approvals in both Sézary syndrome and mycosis fungoides. Innate Pharma is eligible for an additional $40 million in near-term milestone payments and up to $465 million in further payments if Sobi exercises its option for global development rights, along with tiered double-digit royalties on future sales. The partnership supports Innate's development of lacutamab, a first-in-class anti-KIR3DL2 antibody that has received FDA Fast Track and Breakthrough Therapy designations, while expanding Sobi's rare disease portfolio.
• In April 2026, (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on therapies for rare diseases with unmet medical needs, announced that the Data Monitoring Committee has completed the interim efficacy review of the pivotal Phase III FLASH2 trial evaluating HyBryteTM (Synthetic Hypericin) for cutaneous T-cell lymphoma (CTCL). Based on the interim analysis criteria, the committee recommended discontinuing the study due to futility.
• In December 2025, Citius Oncology (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (Nasdaq: CTXR), announced the commercial launch of LYMPHIRTM (denileukin diftitox-cxdl). LYMPHIR is a novel IL-2 receptor-targeted fusion protein approved by the U.S. FDA for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) who have previously received at least one systemic therapy.
• In November 2025, Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with significant unmet needs, announced that it has successfully completed the planned enrollment of 50 patients for the interim analysis of its 80-patient, confirmatory Phase 3, double-blind, placebo-controlled trial assessing HyBryteTM (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). The FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) confirmatory Phase 3 study expands on results from the earlier statistically significant Phase 3 FLASH trial, along with findings from a recent comparative study (HPN-CTCL-04) and a current investigator-initiated study.
• As estimated, the largest market size for Cutaneous T-cell Lymphoma (CTCL) is observed in the United States in 2022, and it is expected to expand at a Compound Annual Growth Rate (CAGR) of approximately 3%.
• In May 2025, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced the upcoming presentation of long-term follow-up results from the Phase 2 TELLOMAK study, which is assessing lacutamab an anti-KIR3DL2 monoclonal antibody in patients with Sézary syndrome (SS) and mycosis fungoides (MF), two uncommon and aggressive subtypes of cutaneous T-cell lymphoma (CTCL). These findings will be shared at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, Illinois.
• In February 2025, Innate Pharma received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for its lead candidate, lacutamab, for the treatment of adults with relapsed or refractory Sézary syndrome. Lacutamab is a pioneering antibody that specifically targets the killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2) to trigger cytotoxic activity. The therapy is currently under clinical investigation for its potential in treating cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma.
• In January 2025, Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases with unmet medical needs, has shared an interim update from an open-label, investigator-initiated study (IIS) evaluating prolonged use of HyBryteTM (synthetic hypericin) for up to 12 months in patients with early-stage cutaneous T-cell lymphoma (CTCL). The study is being led by Dr. Ellen Kim, Director of the Penn Cutaneous Lymphoma Program, Vice Chair of Clinical Operations in the Dermatology Department, and Professor of Dermatology at the Hospital of the University of Pennsylvania. Dr. Kim also played a key role as a lead enroller in the Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial investigating HyBryteTM in early-stage CTCL.
• In December 2024, Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with high unmet needs, has announced the initiation of patient enrollment for its confirmatory Phase 3 clinical trial of HyBryteTM (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL). This new study, titled FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2), is designed to validate findings from the prior statistically significant Phase 3 FLASH trial. It is further supported by data from a recent successful comparative study (HPN-CTCL-04) and an ongoing investigator-initiated trial, reinforcing the trial's foundation.
• Across the 7MM, the United States held the largest share of the Cutaneous T-cell Lymphoma market in 2024, accounting for approximately 70% of total revenue.
• The Cutaneous T-cell Lymphoma market in the United States generated revenue of around USD 700 million in 2024.
• Among the EU4 and the UK, Germany led the Cutaneous T-cell Lymphoma market in 2024, with a market size of approximately USD 70 million.
• In 2024, Japan represented the second-largest Cutaneous T-cell Lymphoma market among the 7MM, with an estimated market value of about USD 90 million.
• In 2024, the United States recorded the highest number of CTCL cases across the 7MM, with approximately 3,050 cases, and this figure is expected to rise by 2034.
• Across the 7MM, around 7,250 new CTCL cases were reported in 2024, with a majority occurring among males.
• In the United States, mycosis fungoides accounted for the majority of type-specific CTCL cases in 2024.
• Among the EU4 and the UK, Germany recorded the largest share of CTCL incident cases in 2024, with approximately 760 cases.
• Key Cutaneous T-cell Lymphoma Companies: Citius Pharmaceuticals, Soligenix, 4SC AG, Innate Pharma, Galderma R&D, Kyowa Kirin, Inc, oligenix, Ligand Pharmaceuticals, Bausch Health Americas, Inc., BioCryst Pharmaceuticals, Novartis, Celgene, Soligenix, Pfizer, Bioniz Therapeutics, Eisai Inc., Merck Sharp & Dohme LLC, and others
• Key Cutaneous T-cell Lymphoma Therapies: I/ONTAK, HyBryte, Resminostat, Lacutamab, CD11301, Mogamulizumab, Hypericin, ONTAK (denileukin difitox, DAB389IL-2), Bexarotene, Forodesine 200 mg, Panobinostat, romidepsin (depsipeptide, FK228), SGX301 (synthetic hypericin), Ritlecitinib, BNZ132-1-40, ONTAK Pembrolizumab, and others
• According to the research conducted by Rangoonwala et al. in 2022, Mycosis Fungoides (MF) stands as the most prevalent subtype among Cutaneous T-cell Lymphomas (CTCLs), accounting for roughly 50% of all CTCL cases. The incidence rate of MF appears to be nearly twice as frequent in males, with individuals typically diagnosed at a median age between 55 and 60 years old.
• The Cutaneous T-cell Lymphoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cutaneous T-cell Lymphoma pipeline products will significantly revolutionize the Cutaneous T-cell Lymphoma market dynamics.

Cutaneous T-cell Lymphoma Overview
Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that primarily affects the skin. It arises when T-cells (a type of white blood cell) become cancerous and target the skin, leading to red, scaly patches, plaques, or tumors. The most common forms of CTCL include Mycosis Fungoides and Sézary Syndrome. While it often progresses slowly, advanced stages may affect lymph nodes, blood, and internal organs. Treatment depends on the disease stage and may involve topical therapies, phototherapy, systemic medications, or immunotherapy.

Get a Free sample for the Cutaneous T-cell Lymphoma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Cutaneous T-cell Lymphoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cutaneous T-cell Lymphoma Epidemiology Segmentation:
The Cutaneous T-cell Lymphoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Cutaneous T-cell Lymphoma
• Prevalent Cases of Cutaneous T-cell Lymphoma by severity
• Gender-specific Prevalence of Cutaneous T-cell Lymphoma
• Diagnosed Cases of Episodic and Chronic Cutaneous T-cell Lymphoma

Download the report to understand which factors are driving Cutaneous T-cell Lymphoma epidemiology trends @ Cutaneous T-cell Lymphoma Epidemiology Forecast
https://www.delveinsight.com/sample-request/cutaneous-t-cell-lymphoma-ctcl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Cutaneous T-cell Lymphoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cutaneous T-cell Lymphoma market or expected to get launched during the study period. The analysis covers Cutaneous T-cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cutaneous T-cell Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cutaneous T-cell Lymphoma Therapies and Key Companies
• I/ONTAK: Citius Pharmaceuticals
• HyBryte: Soligenix
• Resminostat: 4SC AG
• Lacutamab: Innate Pharma
• CD11301: Galderma R&D
• Mogamulizumab: Kyowa Kirin, In
• Hypericin: oligenix
• ONTAK (denileukin difitox, DAB389IL-2): Ligand Pharmaceuticals
• Bexarotene: Bausch Health Americas, Inc.
• Forodesine 200 mg: BioCryst Pharmaceuticals
• Panobinostat: Novartis
• romidepsin (depsipeptide, FK228): Celgene
• SGX301 (synthetic hypericin): Soligenix
• Ritlecitinib: Pfizer
• BNZ132-1-40: Bioniz Therapeutics
• ONTAK: Eisai Inc.
• Pembrolizumab: Merck Sharp & Dohme LLC

Discover more about therapies set to grab major Cutaneous T-cell Lymphoma market share @ Cutaneous T-cell Lymphoma Treatment Landscape
https://www.delveinsight.com/sample-request/cutaneous-t-cell-lymphoma-ctcl-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Cutaneous T-cell Lymphoma Market Drivers
• Rising disease awareness and diagnosis: Greater recognition of cutaneous T-cell lymphoma (CTCL), including mycosis fungoides and Sézary syndrome, is supporting earlier diagnosis and treatment initiation.
• Growing demand for targeted therapies: Increasing adoption of targeted and immunomodulatory treatments, including monoclonal antibodies, antibody-drug conjugates, and other novel therapies, is expanding treatment options.
• Advancing clinical pipeline: Ongoing research into innovative therapies, including immune-based, targeted, and combination approaches, is expected to strengthen the CTCL treatment landscape.
• Increasing unmet medical need: Limited curative treatment options, disease recurrence, and progression to advanced stages are driving demand for more effective and durable therapies.
• Regulatory and R&D activity: Continued clinical development, regulatory approvals, and investment by pharmaceutical companies are supporting innovation and market expansion.

Cutaneous T-cell Lymphoma Market Barriers
• Disease rarity and limited patient population: CTCL is a relatively uncommon malignancy, which can restrict the commercial potential of therapies and make patient recruitment for clinical trials challenging.
• Diagnostic complexity: Symptoms can resemble common dermatological conditions, potentially leading to delayed diagnosis and treatment, particularly during early disease stages.
• High treatment costs: Advanced targeted therapies and biologics can carry substantial costs, creating affordability and reimbursement challenges for patients and healthcare systems.
• Limited treatment options for advanced disease: Patients with advanced or relapsed/refractory CTCL may have limited effective therapeutic choices, with treatment responses varying considerably.
• Clinical trial challenges: The heterogeneous nature of CTCL, relatively small patient populations, and difficulties in establishing consistent endpoints can complicate clinical development and regulatory approval.

Scope of the Cutaneous T-cell Lymphoma Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Cutaneous T-cell Lymphoma Companies: Citius Pharmaceuticals, Soligenix, 4SC AG, Innate Pharma, Galderma R&D, Kyowa Kirin, Inc, oligenix, Ligand Pharmaceuticals, Bausch Health Americas, Inc., BioCryst Pharmaceuticals, Novartis, Celgene, Soligenix, Pfizer, Bioniz Therapeutics, Eisai Inc., Merck Sharp & Dohme LLC, and others
• Key Cutaneous T-cell Lymphoma Therapies: I/ONTAK, HyBryte, Resminostat, Lacutamab, CD11301, Mogamulizumab, Hypericin, ONTAK (denileukin difitox, DAB389IL-2), Bexarotene, Forodesine 200 mg, Panobinostat, romidepsin (depsipeptide, FK228), SGX301 (synthetic hypericin), Ritlecitinib, BNZ132-1-40, ONTAK Pembrolizumab, and others
• Cutaneous T-cell Lymphoma Therapeutic Assessment: Cutaneous T-cell Lymphoma current marketed and Cutaneous T-cell Lymphoma emerging therapies
• Cutaneous T-cell Lymphoma Market Dynamics: Cutaneous T-cell Lymphoma market drivers and Cutaneous T-cell Lymphoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Cutaneous T-cell Lymphoma Unmet Needs, KOL's views, Analyst's views, Cutaneous T-cell Lymphoma Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.